These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36997001)

  • 21. Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.
    Khanlari M; Medeiros LJ; Lin P; Xu J; You MJ; Tang G; Yin CC; Wang W; Qiu L; Miranda RN; Bueso-Ramos CE; Li S
    Mod Pathol; 2022 Mar; 35(3):419-426. PubMed ID: 34608246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas.
    Seegmiller AC; Garcia R; Huang R; Maleki A; Karandikar NJ; Chen W
    Mod Pathol; 2010 Jul; 23(7):909-20. PubMed ID: 20348878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.
    Havelange V; Ameye G; Théate I; Callet-Bauchu E; Mugneret F; Michaux L; Dastugue N; Penther D; Barin C; Collonge-Rame MA; Baranger L; Terré C; Nadal N; Lippert E; Laï JL; Cabrol C; Tigaud I; Herens C; Hagemeijer A; Raphael M; Libouton JM; Poirel HA;
    Genes Chromosomes Cancer; 2013 Jan; 52(1):81-92. PubMed ID: 23012230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinicopathological and molecular genetic features of Burkitt-like lymphoma with 11q aberration].
    Zhang YP; Zhang L; Zhang DD; Wang GN; Zhao WG; Jian XY; Li WC
    Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):604-608. PubMed ID: 34078047
    [No Abstract]   [Full Text] [Related]  

  • 25. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
    Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD38, CD39, and BCL2 differentiate disseminated forms of high-grade B-cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Marianini P; Lacheretz-Szablewski V; Almeras M; Moreaux J; Bret C
    Cytometry B Clin Cytom; 2024 Nov; 106(6):448-464. PubMed ID: 39295433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
    J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell Lymphoma, Not Otherwise Specified.
    Qiu L; Lin P; Khanlari M; Xu J; Cohen EN; Garces S; Miranda RN; Wang W; Fang H; Bueso-Ramos CE; Medeiros LJ; Li S
    Mod Pathol; 2023 Dec; 36(12):100349. PubMed ID: 37820764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.
    Johnson PC; Abramson JS
    Oncology (Williston Park); 2022 Aug; 36(8):499-505. PubMed ID: 36001789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.
    Lap CJ; Nassereddine S; Dunleavy K
    Curr Treat Options Oncol; 2021 Jun; 22(7):60. PubMed ID: 34097157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic progression of post-transplant Burkitt-like lymphoma case with 11q-Gain/Loss and MYC amplification.
    Grygalewicz B; Woroniecka R; Rymkiewicz G; Rygier J; Malawska N; Blachnio K; Bystydzienski Z; Borysiuk A; Nowakowska B; Pienkowska-Grela B
    Cancer Genet; 2020 Jul; 245():1-5. PubMed ID: 32531723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining and treating high-grade B-cell lymphoma, NOS.
    Olszewski AJ; Kurt H; Evens AM
    Blood; 2022 Sep; 140(9):943-954. PubMed ID: 34525177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment for 11q and other chromosomal aberrations in large B-cell/high-grade B cell lymphomas of germinal center phenotype lacking BCL2 expression.
    Ho CC; Naresh K; Liu Y; Wu Y; Gopal AK; Eckel AM
    Cancer Genet; 2024 Jun; 284-285():30-33. PubMed ID: 38520765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.
    Ott G
    Br J Haematol; 2017 Sep; 178(6):871-887. PubMed ID: 28748558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.
    Rodig SJ; Kutok JL; Paterson JC; Nitta H; Zhang W; Chapuy B; Tumwine LK; Montes-Moreno S; Agostinelli C; Johnson NA; Ben-Neriah S; Farinha P; Shipp MA; Piris MA; Grogan TM; Pileri SA; Gascoyne RD; Marafioti T
    Haematologica; 2010 Dec; 95(12):2056-62. PubMed ID: 20823132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?
    Thomas DA; O'Brien S; Faderl S; Manning JT; Romaguera J; Fayad L; Hagemeister F; Medeiros J; Cortes J; Kantarjian H
    Curr Hematol Malig Rep; 2011 Mar; 6(1):58-66. PubMed ID: 21191675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aggressive B-cell non-Hodgkin lymphomas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
    Rodriguez-Pinilla SM; Dojcinov S; Dotlic S; Gibson SE; Hartmann S; Klimkowska M; Sabattini E; Tousseyn TA; de Jong D; Hsi ED
    Virchows Arch; 2024 Jan; 484(1):15-29. PubMed ID: 37530792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
    Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
    Hematol Oncol; 2009 Dec; 27(4):182-5. PubMed ID: 19670467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational landscape of high-grade B-cell lymphoma with
    Künstner A; Witte HM; Riedl J; Bernard V; Stölting S; Merz H; Olschewski V; Peter W; Ketzer J; Busch Y; Trojok P; Bubnoff NV; Busch H; Feller AC; Gebauer N
    Haematologica; 2022 Aug; 107(8):1850-1863. PubMed ID: 34788985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.